{"id":"NCT02082769","sponsor":"Xijing Hospital","briefTitle":"Safety and Efficacy of Oral Febuxostat in Subjects With Gout","officialTitle":"A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2014-03-10","resultsPosted":"2016-02-03","lastUpdate":"2016-02-03"},"enrollment":504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"Febuxostat","otherNames":[]},{"type":"DRUG","name":"Allopurinol","otherNames":[]}],"arms":[{"label":"Febuxostat 40 mg QD","type":"EXPERIMENTAL"},{"label":"Febuxostat 80 mg QD","type":"EXPERIMENTAL"},{"label":"Allopurinol 100mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare febuxostat allopurinol in subjects with gout.","primaryOutcome":{"measure":"Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL)","timeFrame":"Last 3 visits (any last 3 visits up to week 26)","effectByArm":[{"arm":"Febuxostat 40 mg QD","deltaMin":22.5,"sd":null},{"arm":"Febuxostat 80 mg QD","deltaMin":33.5,"sd":null},{"arm":"Allopurinol 100mg QD","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26013187"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":168},"commonTop":["Liver function test abnormalities","Others","Renal function test abnormalities","Abnormal urine protein","Drug allergy"]}}